Three separate phase III clinical trials showed that people with kidney cancer who had undergone nephrectomy (kidney removal) but whose cancer had not yet metastasized, or spread, did not benefit from adjuvant immunotherapy.
The COSMIC-313 trial showed a 27% decrease in the risk of progression or death favoring triplet therapy for kidney cancer.
Kidney cancer research highlights from the 2022 Congress of the European Society for Medical Oncology (ESMO).
Radiation therapy uses targeted doses of high-energy radiation to kill cancer cells and help reduce the size of some tumors.
This is a guest post by Joel Stern, who was diagnosed with stage IV renal cell carcinoma in 2020. It’s been a year since I wrote about my journey with Stage IV renal cell carcinoma…
Being told you have cancer is a traumatic event, one in which patients should be provided with mental health resources to help them cope with their diagnosis but sadly, that is not the standard of care.
“Immunotherapies let me live a normal life,” said Allen Rogers, who was diagnosed with renal cell carcinoma in 2007 at age 51.
Dr. Daniel George answers when and why patients are re-treated with immunotherapy.
By Dr. Daniel GeorgeChair, KCA Medical Steering CommitteeMedical Oncologist, Duke University There is much more to managing kidney cancer than what guidelines say or what clinical trials can test. That’s why we’ve launched a new…
“When I first got diagnosed, mentally I was fine. After the scan this February, it killed my head. We went from ‘kidney is fine’ to ‘it has to come out’ – that was an emotional swing.”